Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.

Revenue
+10.9%
EPS
−351.9%
Free cash flow
−11.5%
Total debt
+3.28%

Quarter to September 2026, against a year earlier

169.01 9.19 −5.16%
Market cap
$10.8B
P/E
0.0×
Fwd P/E
−615×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a

Repligen Corporation (RGEN) Book value per share

Alert me on Book value per share

Repligen Corporation's book value per share at the end of fiscal 2025 was 37.5×, up 6.20% from 35.3× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 37.0×. Over the past ten years it has ranged from 3.7× (fiscal 2015) to 37.5× (fiscal 2025) — the current reading is the highest in ten years. Repligen Corporation ranks 12th of 52 Medical Instruments & Supplies companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 37.5× 6.20%
FY2024 35.3× 0.01%
FY2023 35.3× 2.35%
FY2022 34.5× 8.30%
FY2021 31.8× 9.33%
FY2020 29.1× 32.73%
FY2019 21.9× 55.86%
FY2018 14.1× (9.09%)
FY2017 15.5× 207.79%
FY2016 5.0× 34.66%

Quarterly newest first

Period Book value per share Change
Sep 2026 37.0× (1.21%)
Jun 2026 37.4× 0.20%
Mar 2026 37.4× (0.24%)
Dec 2025 37.5× 1.16%
43 more quarters

Against its own ten years

Low 3.7× High 37.5×
Ten-year median 29.1×
Current reading's percentile 100

Book value per share against peers

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on RGEN